RS67890B1 - Lumateperon za upotrebu u lečenju šizofrenije - Google Patents
Lumateperon za upotrebu u lečenju šizofrenijeInfo
- Publication number
- RS67890B1 RS67890B1 RS20260344A RSP20260344A RS67890B1 RS 67890 B1 RS67890 B1 RS 67890B1 RS 20260344 A RS20260344 A RS 20260344A RS P20260344 A RSP20260344 A RS P20260344A RS 67890 B1 RS67890 B1 RS 67890B1
- Authority
- RS
- Serbia
- Prior art keywords
- lumateperone
- patient
- treatment
- use according
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950828P | 2019-12-19 | 2019-12-19 | |
| EP20900863.0A EP4076461B1 (en) | 2019-12-19 | 2020-12-18 | Lumateperone for use in schizophrenia treatment |
| PCT/US2020/066224 WO2021127572A1 (en) | 2019-12-19 | 2020-12-18 | Methods of schizophrenia treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67890B1 true RS67890B1 (sr) | 2026-04-30 |
Family
ID=76437353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20260344A RS67890B1 (sr) | 2019-12-19 | 2020-12-18 | Lumateperon za upotrebu u lečenju šizofrenije |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210186962A1 (enExample) |
| EP (2) | EP4744678A3 (enExample) |
| JP (2) | JP7727634B2 (enExample) |
| DK (1) | DK4076461T3 (enExample) |
| ES (1) | ES3067760T3 (enExample) |
| FI (1) | FI4076461T3 (enExample) |
| HR (1) | HRP20260406T1 (enExample) |
| LT (1) | LT4076461T (enExample) |
| PL (1) | PL4076461T3 (enExample) |
| PT (1) | PT4076461T (enExample) |
| RS (1) | RS67890B1 (enExample) |
| SI (1) | SI4076461T1 (enExample) |
| SM (1) | SMT202600134T1 (enExample) |
| WO (1) | WO2021127572A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428506B2 (en) | 2012-04-14 | 2016-08-30 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| SMT202600133T1 (it) | 2018-03-23 | 2026-05-12 | Intra Cellular Therapies Inc | Composti organici |
| AU2019328528B2 (en) | 2018-08-31 | 2025-01-23 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP2022549335A (ja) | 2019-09-25 | 2022-11-24 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| IL297333B2 (en) * | 2020-04-17 | 2025-09-01 | Honeybrains Llc | Preparations and methods for treating neuropsychiatric disorders |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000077001A1 (en) | 1999-06-15 | 2000-12-21 | Du Pont Pharmaceuticals Company | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| MX394214B (es) | 2007-03-12 | 2025-03-24 | Intra Cellular Therapies Inc | Sintesis de gamma-carbolinas fusionadas con heterociclo substituido. |
| CA2719824A1 (en) * | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| ES2530090T3 (es) | 2008-03-12 | 2015-02-26 | Intra-Cellular Therapies, Inc. | Sólido de gamma-carbolinas fusionadas con heterociclo sustituido |
| CA2725342C (en) | 2008-05-27 | 2024-02-20 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders |
| KR102967223B1 (ko) * | 2013-12-03 | 2026-05-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| KR20220054908A (ko) | 2014-04-04 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| JP7013454B2 (ja) * | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| CA3082834A1 (en) * | 2017-11-22 | 2019-05-31 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-serine and uses thereof |
| WO2019102240A1 (en) * | 2017-11-27 | 2019-05-31 | Egis Gyógyszergyár Zrt. | Method for the manufacture of lumateperone and its salts |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020047408A1 (en) * | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020112941A2 (en) * | 2018-11-27 | 2020-06-04 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
-
2020
- 2020-12-18 LT LTEPPCT/US2020/066224T patent/LT4076461T/lt unknown
- 2020-12-18 EP EP26153433.3A patent/EP4744678A3/en active Pending
- 2020-12-18 SM SM20260134T patent/SMT202600134T1/it unknown
- 2020-12-18 US US17/127,867 patent/US20210186962A1/en active Pending
- 2020-12-18 DK DK20900863.0T patent/DK4076461T3/da active
- 2020-12-18 EP EP20900863.0A patent/EP4076461B1/en active Active
- 2020-12-18 PL PL20900863.0T patent/PL4076461T3/pl unknown
- 2020-12-18 SI SI202030742T patent/SI4076461T1/sl unknown
- 2020-12-18 WO PCT/US2020/066224 patent/WO2021127572A1/en not_active Ceased
- 2020-12-18 ES ES20900863T patent/ES3067760T3/es active Active
- 2020-12-18 RS RS20260344A patent/RS67890B1/sr unknown
- 2020-12-18 PT PT209008630T patent/PT4076461T/pt unknown
- 2020-12-18 FI FIEP20900863.0T patent/FI4076461T3/fi active
- 2020-12-18 HR HRP20260406TT patent/HRP20260406T1/hr unknown
- 2020-12-18 JP JP2022537550A patent/JP7727634B2/ja active Active
-
2025
- 2025-08-08 JP JP2025133450A patent/JP2025166121A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4076461A4 (en) | 2024-01-03 |
| EP4744678A2 (en) | 2026-05-20 |
| JP7727634B2 (ja) | 2025-08-21 |
| JP2025166121A (ja) | 2025-11-05 |
| HRP20260406T1 (hr) | 2026-05-08 |
| JP2023507584A (ja) | 2023-02-24 |
| LT4076461T (lt) | 2026-06-25 |
| EP4744678A3 (en) | 2026-07-22 |
| DK4076461T3 (da) | 2026-02-23 |
| WO2021127572A1 (en) | 2021-06-24 |
| EP4076461B1 (en) | 2026-01-28 |
| PL4076461T3 (pl) | 2026-04-27 |
| SI4076461T1 (sl) | 2026-05-29 |
| EP4076461A1 (en) | 2022-10-26 |
| US20210186962A1 (en) | 2021-06-24 |
| PT4076461T (pt) | 2026-04-16 |
| FI4076461T3 (fi) | 2026-03-24 |
| SMT202600134T1 (it) | 2026-05-12 |
| ES3067760T3 (en) | 2026-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7727634B2 (ja) | 統合失調症処置方法 | |
| Schwasinger-Schmidt et al. | Other antidepressants | |
| Miyamoto et al. | Antipsychotic drugs | |
| AU2004243096B2 (en) | Carbostyril derivatives and mood stabilizers for treating mood disorders | |
| CN103347517B (zh) | 治疗帕金森病中运动障碍的d3多巴胺受体激动剂 | |
| KR20220147636A (ko) | 칸나비디올 및 에버롤리무스에 의한 복합 결절성 경화증 치료 방법 | |
| JP2023510604A (ja) | 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 | |
| JP2014521659A (ja) | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 | |
| Harvey et al. | Blonanserin versus haloperidol in Japanese patients with schizophrenia: a phase 3, 8‐week, double‐blind, multicenter, randomized controlled study | |
| WO2021016369A1 (en) | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder | |
| TW200803896A (en) | Method of improvement of cognitive function | |
| CA3230291A1 (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| AU2025279746A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| US20230181572A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| US20150174118A1 (en) | Use of laquinimod to delay huntington's disease progression | |
| Schmidt | Pharmacology of NMDA (N-methyl-D-aspartate) receptor antagonists in Alzheimer’s disease | |
| CN104220074A (zh) | 鲁拉西酮新给药方案以及其用于治疗、预防和/或控制至少一种cns病症的用途 | |
| TW202131921A (zh) | Cxcr7拮抗劑與s1p1受體調節劑之組合 | |
| KR20170117185A (ko) | 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘 | |
| Gerlach et al. | Antipsychotics | |
| Robinson et al. | Lumateperone in the Treatment of Schizophrenia: A Review | |
| jilany Khan et al. | Chemical Versatility of Halofuginone; Its Detoxification and Future Pharmacotherapeutic Potentials | |
| Cozza et al. | Psychopharmacology of Depression as a Systemic Illness for Primary and Specialty Care Clinicians Focus on Adverse Drug Reactions and Drug–Drug Interactions | |
| Lepkowsky | Pharmacology of Paroxetine | |
| Lake | Initiatives in Integrative Mental Health. |